No information is available on the clinical use of crizotinib during breastfeeding. Because crizotinib is 91% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 42 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during crizotinib therapy and for 45 days after the last dose.
关于克唑替尼在母乳喂养期间的临床应用尚无可用信息。由于克唑替尼与血浆蛋白的结合率为91%，其在乳汁中的含量可能较低。然而，其半衰期约为42小时，可能会在婴儿体内蓄积。制造商建议在克唑替尼治疗期间及最后一剂后45天内停止母乳喂养。
